Wuhan General Group is a state of Nevada public corporation that trades on the OTC Market under the ticker symbol ‘’WUHN’’.

Wuhan General Group is an alternative medicinal and botanicals company focused on health application of Cannabidiol (CBD) and Psilocybin (magic mushroom) based medicine to the human care industry for cancer, cardiovascular, mental disorders, chronic pain, Chrohn diseases, arthritis, and others in South Africa, Canada, United States, and Europe.

Wuhan General Group operates through its wholly-owned subsidiary MJ MedTech, a nutraceutical biotechnology company that research, develops and commercializes a range of CBD-based products under the Dr. Anna brand.

In addition, its new division, M2BIO aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine and clinical research.

We are committed to supplying medical grade CBD products, superior patient care while increasing shareholders ROI. We’re on track to achieve a positive cash flow in the second quarter of 2019. According to a new estimate from cannabis industry analysts the Brightfield Group, the CBD market alone could hit $22 billion by 2022.

Psilocybin (magic mushroom)
Cannabidiol (CBD)